| Product Code: ETC333684 | Publication Date: Aug 2022 | Updated Date: Aug 2025 | Product Type: Market Research Report | |
| Publisher: 6Wresearch | No. of Pages: 75 | No. of Figures: 35 | No. of Tables: 20 | |
The minimal residual disease testing market size in India was valued at USD 0.56 billion in 2017 and is expected to witness substantial growth over the forecast period owing to increasing prevalence of chronic diseases including acute myeloid leukemia and lymphomas along with improving healthcare infrastructure across the country that has enabled wider accessibility for advanced diagnostic tests such as minimal residual disease testing for early detection of cancer recurrence or progression from its initial stage itself thereby allowing timely treatment options available for patients suffering from these conditions leading ultimately towards its increased adoption rate among end users?.
The outlook for the minimal residual disease (MRD) testing market in India is influenced by several driving factors. Firstly, advancements in medical technology are enabling the detection of residual cancer cells at increasingly lower levels, contributing to improved patient management and treatment outcomes. Secondly, the rising incidence of cancer and the need for precise disease monitoring are driving the adoption of MRD testing. Additionally, the shift towards personalized medicine is emphasizing the importance of accurate disease assessment. These drivers indicate a favorable landscape for the MRD testing market in India.
The minimal residual disease (MRD) testing market in India is significant for cancer diagnostics and treatment monitoring. Challenges include the need for standardized MRD assessment methods across different cancer types and treatment protocols. Adapting to advancements in genomic technologies and ensuring the accessibility of MRD testing in diverse healthcare settings are ongoing challenges. Moreover, addressing data interpretation complexities and patient access to advanced testing methods pose significant challenges.
The minimal residual disease (MRD) testing market in India is crucial for assessing the effectiveness of cancer treatments. The pandemic posed challenges to cancer care and diagnostics. As healthcare services are restored, the demand for MRD testing is likely to resume. Advances in oncology research and the growing importance of personalized medicine could drive the adoption of MRD testing as part of comprehensive cancer treatment strategies.
1 Executive Summary |
2 Introduction |
2.1 Key Highlights of the Report |
2.2 Report Description |
2.3 Market Scope & Segmentation |
2.4 Research Methodology |
2.5 Assumptions |
3 India Minimal Residual Disease Testing Market Overview |
3.1 India Country Macro Economic Indicators |
3.2 India Minimal Residual Disease Testing Market Revenues & Volume, 2021 & 2031F |
3.3 India Minimal Residual Disease Testing Market - Industry Life Cycle |
3.4 India Minimal Residual Disease Testing Market - Porter's Five Forces |
3.5 India Minimal Residual Disease Testing Market Revenues & Volume Share, By Application, 2021 & 2031F |
3.6 India Minimal Residual Disease Testing Market Revenues & Volume Share, By End User, 2021 & 2031F |
4 India Minimal Residual Disease Testing Market Dynamics |
4.1 Impact Analysis |
4.2 Market Drivers |
4.2.1 Increasing prevalence of cancer in India |
4.2.2 Growing awareness about the importance of early cancer detection |
4.2.3 Advancements in technology leading to more accurate and efficient minimal residual disease testing |
4.3 Market Restraints |
4.3.1 High cost associated with minimal residual disease testing |
4.3.2 Lack of skilled healthcare professionals for conducting and interpreting the tests |
4.3.3 Limited access to advanced healthcare facilities in rural areas |
5 India Minimal Residual Disease Testing Market Trends |
6 India Minimal Residual Disease Testing Market, By Types |
6.1 India Minimal Residual Disease Testing Market, By Application |
6.1.1 Overview and Analysis |
6.1.2 India Minimal Residual Disease Testing Market Revenues & Volume, By Application, 2021-2031F |
6.1.3 India Minimal Residual Disease Testing Market Revenues & Volume, By Hematological Malignancy , 2021-2031F |
6.1.4 India Minimal Residual Disease Testing Market Revenues & Volume, By Solid Tumor, 2021-2031F |
6.2 India Minimal Residual Disease Testing Market, By End User |
6.2.1 Overview and Analysis |
6.2.2 India Minimal Residual Disease Testing Market Revenues & Volume, By Hospital and Specialty Clinics, 2021-2031F |
6.2.3 India Minimal Residual Disease Testing Market Revenues & Volume, By Diagnostic Laboratories, 2021-2031F |
6.2.4 India Minimal Residual Disease Testing Market Revenues & Volume, By Research Institutions, 2021-2031F |
6.2.5 India Minimal Residual Disease Testing Market Revenues & Volume, By Other, 2021-2031F |
7 India Minimal Residual Disease Testing Market Import-Export Trade Statistics |
7.1 India Minimal Residual Disease Testing Market Export to Major Countries |
7.2 India Minimal Residual Disease Testing Market Imports from Major Countries |
8 India Minimal Residual Disease Testing Market Key Performance Indicators |
8.1 Adoption rate of minimal residual disease testing technology in India |
8.2 Rate of increase in funding for cancer research and early detection programs |
8.3 Number of collaborations between healthcare institutions and technology companies for improving minimal residual disease testing accuracy |
9 India Minimal Residual Disease Testing Market - Opportunity Assessment |
9.1 India Minimal Residual Disease Testing Market Opportunity Assessment, By Application, 2021 & 2031F |
9.2 India Minimal Residual Disease Testing Market Opportunity Assessment, By End User, 2021 & 2031F |
10 India Minimal Residual Disease Testing Market - Competitive Landscape |
10.1 India Minimal Residual Disease Testing Market Revenue Share, By Companies, 2024 |
10.2 India Minimal Residual Disease Testing Market Competitive Benchmarking, By Operating and Technical Parameters |
11 Company Profiles |
12 Recommendations |
13 Disclaimer |